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Abstract Although we have several acute care medica-
tions for the treatment of migraine, we are always looking
for new medications to treat our patients. Patients often say
that their headaches are not under optimal control and
would be happy to try another medication. Patients look for
faster onset of relief, more complete relief, no recurrent
headache and no adverse events. This article will cover
some new and some anticipated acute care products, CGRP
antagonists, sumatriptan by iontophoretic patch, sumatrip-
tan by needle-free injections, DHE by oral inhalation and
diclofenac potassium in a sachet. Botulinum toxin therapy,
although a preventive measure, will be mentioned at the
end.
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CGRP receptor antagonists
Calcitonin gene-related peptide, closely related structurally
to calcitonin and amylin, has been intensely studied over
the last 20 years as an agent possibly related to migraine
pathophysiology. CGRP is involved in sensory neuro-
transmission and can be found in most sensory nerves,
especially those trigeminovascular afferents in the menin-
ges involved in migraine [1, 2]. It is one of the most potent
vasodilators known. CGRP levels measured in the jugular
venous system are elevated after migraine and cluster
headache attacks, and are normalized by therapy with
sumatriptan. For years, it was thought that blocking its
dilating effect might help in treating migraine and its
antagonism held promise to be a novel strategy to relieve
migraine headache. It is now known to effectively block
migraine pain without overt vasoconstriction. If and when
they gain approval in the USA by the FDA and in other
countries, CGRP receptor antagonists would be the ﬁrst
non-serotonergic, non-vasoconstricting, migraine-speciﬁc
medication. CGRP has been shown to have several sites of
action, including blood vessels, mast cells in the meninges
and as a facilitator of pain transmission the brain stem [3].
CGRP receptors have been found in trigeminal ganglion, in
the brain stem in neurons of the trigeminal nucleus caudalis
and in smooth muscle of the meningeal vasculature [6].
CGRP can be blocked by a fragment of the peptide con-
taining amino acids 8–37 (CGRP 8–37).
The ﬁrst effective CGRP receptor blocker was
BIBN4096 (olcegepant). It was reported that intravenous
administration helped a signiﬁcant number of patients
versus placebo, without constricting blood vessels in pre-
clinical studies [4]. Telcagepant, previously termed
MK-0974, was the ﬁrst reported oral formulation of a
CGRP receptor antagonist. It has been reported to work
well in migraine in a phase IIB study published in Neu-
rology and recently in a phase III study published in Lancet
[5, 6]. Preclinical data suggest that telcagepant is not a
vasoconstrictor, and clinical studies show it to be as
effective as rizatriptan and zolmitriptan and as tolerable as
placebo. It is predicted that this drug could be launched in
2012. It was found to be as effective as zolmitriptan with
fewer adverse events [6].
This was a randomized, parallel treatment, placebo and
active-controlled, double-blind, trial performed at 81 sites
in Europe and the USA of adults with migraine diagnosed
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moderate or severe migraine attacks with either oral tel-
cagepant 150 or 300 mg, zolmitriptan 5 mg, or placebo.
There were ﬁve co-primary endpoints: pain freedom, pain
relief and absence of nausea, photophobia and phonopho-
bia, at 2-h post treatment. According to Dr. Ho’s article,
‘‘1,380 patients were randomly assigned to receive tel-
cagepant 150 mg (n = 333), 300 mg (n = 354), zolmi-
triptan 5 mg (n = 345) or placebo (n = 348). Telcagepant
300 mg was more effective than placebo for pain freedom
[95 (27%) of 353 patients vs. 33 (10%) of 343
(p = 0.0001)], pain relief [194 (55%) of 353 vs. 95 (28%)
of 343 (p = 0.0001)], and absence of phonophobia [204
(58%) of 353 vs. 126 (37%) of 342 (p = 0.0001)], photo-
phobia [180 (51%) of 353 vs. 99 (29%) of 342
(p = 0.0001)], and nausea [229 (65%) of 352 vs. 189
(55%) of 342 (p = 0.0061)]. The efﬁcacy of telcagepant
300 mg and zolmitriptan 5 mg was much the same, and
both were more effective than telcagepant 150 mg.
Adverse events were recorded for 31% taking telcagepant
150 mg, 37% taking telcagepant 300 mg, 51% taking
zolmitriptan 5 mg, and 32% taking placebo [7].’’ The
measurement of 2–24 h sustained pain freedom was
slightly better numerically for telcagepant 300 mg versus
zolmitriptan. This drug may be able to be given to patients
with vascular disease, but that was not studied in this trial
as zolmitriptan is contraindicated in patients with vascular
disease and this will have to be studied in the future.
Transdermal patches
Recently, sumatriptan became the ﬁrst of the seven triptans
to become generic in several countries, which has led to the
development of generic formulations of available products
and to the design of some novel products containing the
generic formulation, including needle-free injection, sub-
lingual, intranasal and patch forms. One of the most inter-
esting products in development, which may address the
unmet need of the nauseated migraineur and/or the patient
who does not absorb oral medication optimally during a
migraine attack, is a sumatriptan patch. NP101, which will
be marketed as Zelrix from NuPathe, is an iontophoretic
patch that delivers sumatriptan transdermally. It utilizes a
small electric current to drive sumatriptan across the skin
delivering 6 or 12 mA/h and maintaining sumatriptan
plasma levels above the target level of 10 ng/ml for greater
than 7 h [8]. There is a linear relationship between the
applied current and drug delivery. As a result, drug delivery
is precisely controlled at desired levels, providing consis-
tent therapeutic drug levels. In pK studies, the patch
delivered sumatriptan more consistently than either the
100 mg oral tablet or 20 mg nasal preparation. This ﬁnding
supports the hypothesis that parenteral administration
(subcutaneous or transdermal) provides more predictable
delivery by bypassing absorption through the GI tract.
At the intended plasma concentrations delivered by the
patch, which were in between those of the 20 mg nasal
spray and 100 mg oral tablet, the patches were well toler-
ated. No subject reported atypical pain and pressure sen-
sations or other common triptan adverse events after related
pruritus, which was generally mild and resolved without
treatment. No subject withdrew from the study due to local
skin irritation. The data suggest that transdermal ionto-
phoretic delivery of sumatriptan with NP101 may offer
signiﬁcant clinical utility for migraine patients, including
circumventing underlying migraine-associated GI distur-
bances including nausea and gastric stasis. The patch also
provides consistent, predictable delivery of desired drug
levels over a 4-h period. This offers the potential to avoid
atypical pain, pressure and other sensations commonly
associated with current triptan formulations. The results of a
recent phase-III trial were released at the American Head-
ache Society meeting in Philadelphia. The 2-h pain relief
was 53% versus 29% placebo. This was signiﬁcant at
p = 0.0001 level. The drug also achieved signiﬁcance over
placebo in the three other parts of the primary endpoint,
nausea free, photophobia free and sonophobia free. The
pain free rate at 2 h was 18 versus 9% for placebo. The
sustained pain relief rate from 2–24 h was 34% for the drug
and 21% for placebo. Therefore, with good 2-h pain relief,
relief of associated symptoms, few adverse events and the
ability to bypass the GI tract, this should be an attractive
alternative to standard oral treatment.
Sumatriptan by needle-free injection
Sumavel DosePro by Zogenix will deliver 6 mg of suma-
triptan subcutaneously through the skin without the use of a
needle. The device is carefully designed to work exactly
the same as the sumatriptan injection. Thus, it has excellent
1- and 2-h pain relief numbers. It is a sophisticated device
that produces a small hole in the skin by the force of the
injection using nitrogen gas ﬁred through a tiny hole in the
glass. The injection takes less than one tenth of a second.
This system was marketed in the USA in January 2010, and
is a good alternative for patients who are concerned about
the needle and those who do not get adequate relieve from
oral triptans.
Oral inhaler for DHE
DHE (dihydroergotamine mesylate) is being developed for
delivery by oral inhalation in a novel, breath-actuated
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than 50 years and still remains the mainstay of treatment at
major headache centers in the USA via the intravenous
route when patients require having already developed
central sensitization. It is usually given three times per day
intravenously. It is also used orally in Europe as a pre-
ventive and intranasally in the USA and Canada as an acute
care medication. The intravenous preparation is often very
effective, but cannot be used at home and many patients
become nauseated or even vomit, despite pretreatment with
an antiemetic. Oral inhalation seems to provide similar
efﬁcacy withthe easeofhome useandfeweradverseevents.
Studies were performed with a specially designed device
called the Tempo Inhaler (MAP Pharma), to deliver DHE
deep into the lung after breath actuation [9]. The drug and
device will be called Levadex. A phase I study of four
doses of orally inhaled DHE delivered by the specially
designed inhaler versus 1 mg of IV DHE (n = 18) was
performed. There was a rapid systemic absorption of DHE
with a tmax of 12 min with a 0.88 mg respirable dose (vs. a
6-min tmax with the IV preparation). The systemic levels
attained were slightly lower than with IV DHE, with the
ratio of AUC 0 to inﬁnity of inhaled versus IV approxi-
mately 0.77. The Tempo inhaler is a proprietary, novel,
breath-actuated device that minimizes oropharyngeal
deposition and therefore swallowing of the drug. Phase II
data shows DHE gives relief that is both rapid and sus-
tained [10]. Phase II results demonstrate that 32% of
patients achieve pain relief as early as 10 min (p = 0.019)
at 0.5 mg dose. This is somewhat lower that the usual dose
IV. DHE delivered by this inhaler was well tolerated in
phase II studies with no serious adverse events. There was
decreased nausea and no clinically signiﬁcant changes
observed in pulmonary function tests, clinical laboratory
ﬁndings, heart rate, blood pressure or respiratory rate.
Phase III results presented in Philadelphia at the Inter-
national Headache Congress in September 2009 showed a
2-h headache relief of 59 versus 35% placebo. This was
signiﬁcant at p = 0.0001 level. The 2–24 h sustained
headache relief rate was 44% for Levadex and 20% for
placebo and the 2–48 h sustained pain free rate was 36
versus 17%. Adverse events were low and nausea and
vomiting surprisingly low (4.5 vs. 2% for nausea and 2 vs.
0.1% for vomiting). This low level in comparison to IV
DHE probably is related to a lower cmax. Other important
ﬁndings were efﬁcacy of Levadex given more than 8 h
after the start of the headache, 49 versus 25% for the
placebo and efﬁcacy in disabling migraine, early morning
migraine and menstrually related migraine.
Levadex is expected to get FDA approval in 2011 and
should be a good drug for patients not responding well to
oral triptans or for patients who are more than 6–8 h into
their migraine attack.
Diclofenac potassium for oral solution
Cambia was approved for acute treatment of migraine in
June 2009 and will be marketed in the spring of 2010 by
Nautilus Neurosciences. It comes in a small packet or
sachet and its contents are dissolved in water. As it is in
solution, it gains rapid entry into the small intestine and has
a faster tmax and onset of action than its tablet form. The
2-h pain relief is 65 versus 41% for placebo. Cambia will
be the only NSAID approved for the acute treatment of
migraine and could be an excellent drug for milder
migraines, especially for patients with more frequent
headaches.
Neurotoxin therapy: botulinum toxin injections
Although the exact mechanism of action of botulinum
toxin type A (Botox) injections as a treatment for migraine
are unknown, they are probably independent of the toxin’s
anti-cholinergic effects at the neuromuscular junction. It is
no longer believed that the relaxation or induced weakness
of muscles contributes to the therapeutic effect; instead
inhibition of peripheral sensitization, leading to the inhi-
bition of central sensitization through the blocking of
glutamate, substance P and CGRP peripherally, is thought
to lead to the therapeutic effect. There have been many
positive open trials and a few double-blind, controlled
studies with conﬂicting reports of efﬁcacy.
In a chronic migraine trail, in which the primary end-
point was not reached, efﬁcacy was shown only in a sub-
group not taking preventive medication and having more
than 15 headache days per month [11]. A recent study to
compare the effectiveness of treatment of transformed
migraine between botulinum toxin type A and topiramate
demonstrated that both groups had signiﬁcantly fewer
headaches compared with baseline 6 months after the start
of therapy. At 9 months, the two treatments were equiva-
lent. More patients in the topiramate group dropped out of
the study due to adverse events [12]. Another recent study
compared botulinum toxin type A with divalproex in epi-
sodic and chronic migraine. The data demonstrate that both
treatments showed a signiﬁcant reduction in disability with
fewer adverse events in the botulinum toxin type A treated
group [13].
Two large, double-blind, placebo-controlled, random-
ized, phase III trials were performed in patients with
transformed migraine, who were not on preventive medi-
cation. The results were released in Philadelphia at the
International Headache Congress in September, 2009, a
year after a press release was issued by Allergan [14]i n
September 2008 about the results. The primary endpoint
for the ﬁrst trial was the change from baseline in the
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second trial, the primary endpoint was the change in
the number of headache days at the end of 3 months. At the
request of Allergan, the FDA permitted a change in
the primary endpoint in the second study prior to unlocking
the data. The change was from the change from baseline
in the number of headache episodes at 3 months to the
change from baseline in the number of headache days
(which is what the FDA had initially suggested for the
primary endpoint).
The results showed that the ﬁrst trial did not reach its
primary endpoint and was negative. In the second trial,
both the primary and secondary endpoints showed statis-
tically signiﬁcant beneﬁt of botulinum toxin type A treat-
ment over placebo injections. Patients treated with
botulinum toxin type A demonstrated a greater decrease in
both number of headache days (p = 0.001) (primary end-
point) and number of headache episodes (p = 0.003)
(secondary endpoint). If the FDA suggested endpoint had
been used (decrease in number of headache days), the ﬁrst
study would also have been positive. A meta-analysis of
the two studies, one positive and one negative, was positive
for all primary and secondary endpoints. Allergan has ﬁled
for an indication for the treatment of chronic migraine with
botulinum toxin type A and expects a decision from the
FDA by early 2011.
Conclusion
There are many new acute care and preventive therapies
being investigated for the treatment of migraine. A few of
them have been presented here. I am cautiously optimistic
that some of the above treatments that are not yet available
will make it to the clinic and will be effective additions to
the headache specialist’s armamentarium.
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